Alpha 2-antiplasmin (or α2-antiplasmin or plasmin inhibitor) is a serine protease inhibitor (serpin) responsible for inactivating plasmin, an important enzyme that participates in fibrinolysis and degradation of various other proteins. This protein is encoded by the SERPINF2 gene.[1]
Fibrinolysis (simplified). Blue arrows denote stimulation, and red arrows inhibition.
Very few cases (<20) of A2AP deficiency have been described. As plasmin degrades blood clots, impaired inhibition of plasmin leads to a bleeding tendency, which was severe in the cases reported.
Martí-Fàbregas J, Borrell M, Cocho D, et al. (2008). "Change in hemostatic markers after recombinant tissue-type plasminogen activator is not associated with the chance of recanalization". Stroke39 (1): 234–6. doi:10.1161/STROKEAHA.107.493767. PMID 18048863.
Nielsen VG (2007). "Hydroxyethyl starch enhances fibrinolysis in human plasma by diminishing alpha2-antiplasmin-plasmin interactions". Blood Coagul. Fibrinolysis18 (7): 647–56. doi:10.1097/MBC.0b013e3282a167dc (inactive 2008-06-22). PMID 17890952.
Sazonova IY, Thomas BM, Gladysheva IP, et al. (2007). "Fibrinolysis is amplified by converting alpha-antiplasmin from a plasmin inhibitor to a substrate". J. Thromb. Haemost.5 (10): 2087–94. doi:10.1111/j.1538-7836.2007.02652.x. PMID 17883703.
Mutch NJ, Thomas L, Moore NR, et al. (2007). "TAFIa, PAI-1 and alpha-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots". J. Thromb. Haemost.5 (4): 812–7. doi:10.1111/j.1538-7836.2007.02430.x. PMID 17388801.
Christiansen VJ, Jackson KW, Lee KN, McKee PA (2007). "The effect of a single nucleotide polymorphism on human alpha 2-antiplasmin activity". Blood109 (12): 5286–92. doi:10.1182/blood-2007-01-065185. PMID 17317851.
Hayashido Y, Hamana T, Ishida Y, et al. (2007). "Induction of alpha2-antiplasmin inhibits E-cadherin processing mediated by the plasminogen activator/plasmin system, leading to suppression of progression of oral squamous cell carcinoma via upregulation of cell-cell adhesion". Oncol. Rep.17 (2): 417–23. PMID 17203182.
Shibata N, Kawarai T, Meng Y, et al. (2007). "Association studies between the plasmin genes and late-onset Alzheimer's disease". Neurobiol. Aging28 (7): 1041–3. doi:10.1016/j.neurobiolaging.2006.05.028. PMID 16828203.
Liu T, Qian WJ, Gritsenko MA, et al. (2006). "Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry". J. Proteome Res.4 (6): 2070–80. doi:10.1021/pr0502065. PMID 16335952.
Lee KN, Jackson KW, Christiansen VJ, et al. (2004). "A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion". Blood103 (10): 3783–8. doi:10.1182/blood-2003-12-4240. PMID 14751930.
Anderson NL, Polanski M, Pieper R, et al. (2004). "The human plasma proteome: a nonredundant list developed by combination of four separate sources". Mol. Cell Proteomics3 (4): 311–26. doi:10.1074/mcp.M300127-MCP200. PMID 14718574.
Kapadia C, Yousef GM, Mellati AA, et al. (2004). "Complex formation between human kallikrein 13 and serum protease inhibitors". Clin. Chim. Acta339 (1-2): 157–67. doi:10.1016/j.cccn.2003.10.009. PMID 14687906.
Matsuno H, Okada K, Ueshima S, et al. (2004). "Alpha2-antiplasmin plays a significant role in acute pulmonary embolism". J. Thromb. Haemost.1 (8): 1734–9. doi:10.1046/j.1538-7836.2003.00252.x. PMID 12911586.
Magklara A, Mellati AA, Wasney GA, et al. (2003). "Characterization of the enzymatic activity of human kallikrein 6: Autoactivation, substrate specificity, and regulation by inhibitors". Biochem. Biophys. Res. Commun.307 (4): 948–55. doi:10.1016/S0006-291X(03)01271-3. PMID 12878203.
Cardoso C, Leventer RJ, Ward HL, et al. (2003). "Refinement of a 400-kb critical region allows genotypic differentiation between isolated lissencephaly, Miller-Dieker syndrome, and other phenotypes secondary to deletions of 17p13.3". Am. J. Hum. Genet.72 (4): 918–30. doi:10.1086/374320. PMID 12621583.
Frank PS, Douglas JT, Locher M, et al. (2003). "Structural/functional characterization of the alpha 2-plasmin inhibitor C-terminal peptide". Biochemistry42 (4): 1078–85. doi:10.1021/bi026917n. PMID 12549929.
Strausberg RL, Feingold EA, Grouse LH, et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences". Proc. Natl. Acad. Sci. U.S.A.99 (26): 16899–903. doi:10.1073/pnas.242603899. PMID 12477932.
Turner RB, Liu L, Sazonova IY, Reed GL (2002). "Structural elements that govern the substrate specificity of the clot-dissolving enzyme plasmin". J. Biol. Chem.277 (36): 33068–74. doi:10.1074/jbc.M203782200. PMID 12080056.
Askew YS, Pak SC, Luke CJ, et al. (2002). "SERPINB12 is a novel member of the human ov-serpin family that is widely expressed and inhibits trypsin-like serine proteinases". J. Biol. Chem.276 (52): 49320–30. doi:10.1074/jbc.M108879200. PMID 11604408.
Uszynski M, Klyszejko A, Zekanowska E (2001). "Plasminogen, alpha(2)-antiplasmin and complexes of plasmin-alpha(2)-antiplasmin (PAP) in amniotic fluid and blood plasma of parturient women". Eur. J. Obstet. Gynecol. Reprod. Biol.93 (2): 167–71. doi:10.1016/S0301-2115(00)00283-9. PMID 11074138.
Hevessy Z, Patthy A, Kárpáti L, Muszbek L (2000). "alpha(2)-plasmin inhibitor is a substrate for tissue transglutaminase: an in vitro study". Thromb. Res.99 (4): 399–406. doi:10.1016/S0049-3848(00)00261-9. PMID 10963790.
